Appointment of Dr. Jennifer Kaufman-Shaw as Vice-President, Intellectual Property and Legal Affairs

September 11, 2014 – Zymeworks Inc.

Vancouver, Canada (September 11, 2014) – Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced the appointment of Dr. Jennifer Kaufman-Shaw as Vice-President, Intellectual Property and Legal Affairs.

Dr. Kaufman-Shaw joins Zymeworks with over 20 years in global intellectual property strategy and management. She has extensive experience in the biotechnology and pharmaceutical sectors, including having been part of the management teams at QLT Inc. and Sirius Genomics Inc., and helping co-found ImStar Therapeutics Inc. During her times at QLT and Sirius, she was instrumental in the development and execution of intellectual property strategies while also playing a major role in supporting licensing activities. Dr. Kaufman-Shaw holds both a Ph.D. and a LL.B. from the University of Alberta. “I’m very pleased to welcome Jennifer to the Zymeworks team at a time of great excitement and growth for the Company,” says Dr. Ali Tehrani, President and CEO of Zymeworks. “Jennifer will be leading our intellectual property group, and will assume responsibility for advancing Zymeworks’ global IP strategy and patent portfolio, including our best-in-class bi-specific therapeutics programs, and our therapeutic and computational platforms. About Zymeworks Inc. Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s novel Azymetric™ and AlbuCORE™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.

More information on Zymeworks can be found at

Contact: Zymeworks Inc. Ali Tehrani, President & CEO Source: Zymeworks Inc.